MedPath

Nasal Carrying by Staphylococcus Aureus ST398 Strains in Community and Hospital Settings

Conditions
Staphylococcus Aureus Nasal Carriage
Interventions
Procedure: Nasal swab
Registration Number
NCT03869255
Lead Sponsor
Centre Hospitalier Universitaire de Besancon
Brief Summary

The aim of this study was to compare the prevalence of nasal carrying of SA ST398 strains in community and hospital settings, identify the factors associated with colonization of SA ST398, determine the distribution of imported and acquired cases among SA ST398 hospital cases and characterize the genetic structure of the ST398 SA population involved in colonization.

Detailed Description

Staphylococcus aureus (SA) is a ubiquitous bacterium, part of the human commensal flora. The mucosa of the anterior nasal cavities represents the preferred site of colonization of SA. The SA ST398 clone, belonging to CC 398, was initially described as a zoonotic agent initially identified in France and the Netherlands. In fact, ST398 strains are separated into two distinct populations: a methicillin-resistant SA population (SAMR) with notion of contact with animals and a more virulent methicillin-sensitive SA population (SAMS) than its counterpart, isolated from serious human infections and without notion of exposure to farm animals. Recently, we have shown that, in SA bacteremia, all strains of SA ST398 are sensitive to methicillin and that the prevalence of ST398 among all SAMS responsible for bacteremia at Besançon University Hospital increased between 2009 and 2014, increased from 4 to 15%. However, we were unable to study nasal colonization to support the mode of acquisition of SA ST398 (community vs. healthcare acquisition).

Recruitment & Eligibility

Status
UNKNOWN
Sex
All
Target Recruitment
2000
Inclusion Criteria
  • the selection criteria for blood donation
  • age ≥ 18 years old
  • No refusal of the person
Exclusion Criteria
  • None

For hospitalized patients :

Inclusion Criteria:

  • age ≥ 18 years old
  • hospitalization in one of the services participating in the study
  • no refusal of the person

Exclusion Criteria:

  • None

Study & Design

Study Type
OBSERVATIONAL
Study Design
Not specified
Arm && Interventions
GroupInterventionDescription
Hospitalized patientsNasal swabWithin 48 hours of admission to participating departments, all patiens will be included. A nasal swab will be performed within the first 48 hours and on the 7th day.
Community patientsNasal swabPeople coming to donate blood in "Etablissement Français du Sang" will be included and a nasal swab will be performed
Primary Outcome Measures
NameTimeMethod
Number of patients nasal carrying of SA ST398 strains in community and hospital settingsOne day

Number of patients with SA ST398 positive nasal swab in community will be compared with number of patients with SA ST398 positive nasal swab in hospital

Secondary Outcome Measures
NameTimeMethod
Number of patietns with specific Clinical and demographic data associated with nasal carrying of SA ST398One day

Clinical and demographic (sex, age, gender, comorbidities, tabaco...) data will be compared between patients with SA ST398 positive nasal swab and SA ST398 negative nasal swab

Number of patients with SA ST398 positive nasal swab to seven days of hospitalization7 days

Number of patients with SA ST398 positive nasal swab to seven days of hospitalization will be compared with the number of patients with SA ST398 positive nasal swab within the first 48 hours of hospitalization

Number of virulence gene in SA ST 398 strainsOne day

Presence of virulence gene in SA ST 398 strains

Trial Locations

Locations (1)

CHU de Besançon

🇫🇷

Besançon, France

© Copyright 2025. All Rights Reserved by MedPath